Polymerized Peptides Targeting Amyloid Conformational Epitopes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapeutic approaches for amyloid diseases, such as Alzheimer's, face challenges including potential cell-mediated toxicity, non-specific targeting of amyloidogenic proteins, and poor efficacy, particularly in reducing amyloid burden and addressing tau-related pathology.
Innovation Solution
Development of polymerized peptides and fusion peptides with specific amino acid sequences that generate a targeted immunological response to conformational epitopes shared by amyloidogenic proteins, avoiding amino acid sequence homology with human proteins to minimize toxicity and enhance specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional immunotherapy is used to target amyloid proteins, then amyloid burden is reduced, but cell-mediated toxicity and non-specific targeting occur
Solution Approach 1:
The patent changes the chemical structure parameter of the immunogen by using polymerized peptides with specific amino acid sequences that lack homology to human proteins, thereby maintaining immunogenicity while eliminating cross-reactivity with normal human proteins and reducing cell-mediated toxicity
Solution Approach 2:
The patent introduces polymerized peptides as an intermediary immunogen that bridges the gap between complete amyloid proteins and simple peptide fragments, providing conformational epitope recognition without the harmful effects of whole protein immunization
2Quantity of substance
If conventional immunotherapy targets amyloidogenic proteins, then amyloid deposition is reduced, but specificity is compromised due to amino acid sequence homology with human proteins
Solution Approach 1:
The patent modifies the amino acid sequence parameters of the immunogen to create peptides that are structurally similar to amyloidogenic proteins but lack homology to human proteins, ensuring specific targeting without cross-reactivity
Solution Approach 2:
The patent creates a simplified copy of the amyloidogenic protein structure using peptide sequences that replicate the conformational epitopes necessary for antibody recognition without containing the harmful amino acid sequences found in human proteins
3Quantity of substance
If conventional immunotherapy is applied, then some amyloid reduction is achieved, but cognitive benefits are minimal and efficacy is poor
Solution Approach 1:
The patent applies preliminary immunization with polymerized peptides to establish a specific immune response before significant amyloid pathology develops, maximizing the potential for cognitive benefit through early intervention
Solution Approach 2:
The patent changes the immunogen formulation parameters to use polymerized peptides with optimized amino acid sequences that enhance immunogenicity and specificity, thereby improving the overall efficacy and cognitive outcomes of the therapy
Data Source
AI summary
The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.